Straits Times Index
3,342.73 +3.79 (+0.11%) Nikkei
38,527.60 -309.86 (-0.80%) Hang Seng
18,503.00 +58.89 (+0.32%) FTSE 100
8,232.04 -30.71 (-0.37%) Bitcoin USD
70,894.34 +1,722.71 (+2.49%) CMC Crypto 200
1,477.25 +30.10 (+2.08%)
Genscript Biotech Corporation (1548.HK)
| Previous close | 9.100 |
| Open | 9.190 |
| Bid | 9.070 x 0 |
| Ask | 9.080 x 0 |
| Day's range | 8.980 - 9.280 |
| 52-week range | 7.430 - 24.950 |
| Volume | |
| Avg. volume | 16,747,334 |
| Market cap | 19.3B |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.350 |
| Earnings date | 16 Aug 2024 - 17 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 05 Jun 2017 |
| 1y target est | 27.68 |
PR NewswireGenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications
GenScript Biotech Corporation, a global leader in life science research tools and services, has today announced the expansion of its in vitro transcription (IVT) RNA synthesis portfolio to include self-amplifying RNA (saRNA). This cutting-edge addition reinforces GenScript's position at the forefront of IVT RNA technology, offering a new and novel format for researchers working in applications such as vaccine, cancer immunotherapy, and gene or cell therapy development.
Business WireMultiply Labs and GenScript Biotech Corporation Collaborate to Automate the Cell Isolation and Enrichment Phase of Cell Therapy Manufacturing
SAN FRANCISCO, April 25, 2024--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corporation (GenScript), one of the world's leading providers of life-science research tools and services, today announced a strategic partnership around the automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process.
PR NewswireGenScript Biotech Releases 2023 ESG Report: Deepening Green Development Practices, Constructing Sustainable Future Blueprint
Recently, GenScript Biotech Corporation (HK.1548), a world leader in technologies and services for life science R&D and manufacture, released its 2023 Environmental, Social, and Governance (ESG) report. This report showcases the company's dedicated efforts in ESG governance, corporate social responsibility fulfillment, and environmental conservation practices. It underscores GenScript's unwavering commitment to advancing green initiatives and seamlessly integrating sustainable development strate
